#Global Blood Screening Market

[treethymes]

With the exceptions of North Korea and Cuba, the communist world has merged onto the capitalist highway in a couple different ways during the twenty-first century. As you’ve read, free-trade imperialism and its cheap agricultural imports pushed farmers into the cities and into factory work, lowering the global price of manufacturing labor and glutting the world market with stuff. Forward-thinking states such as China and Vietnam invested in high-value-added production capacity and managed labor organizing, luring links from the global electronics supply chain and jump-starting capital investment. Combined with capital’s hesitancy to invest in North Atlantic production facilities, as well as a disinclination toward state-led investment in the region, Asian top-down planning erased much of the West’s technological edge. If two workers can do a single job, and one worker costs less, both in wages and state support, why pick the expensive one? Foxconn’s 2017 plan to build a U.S. taxpayer–subsidized $10 billion flat-panel display factory in Wisconsin was trumpeted by the president, but it was a fiasco that produced zero screens. The future cost of labor looks to be capped somewhere below the wage levels many people have enjoyed, and not just in the West.

The left-wing economist Joan Robinson used to tell a joke about poverty and investment, something to the effect of: The only thing worse than being exploited by capitalists is not being exploited by capitalists. It’s a cruel truism about the unipolar world, but shouldn’t second place count for something? When the Soviet project came to an end, in the early 1990s, the country had completed world history’s biggest, fastest modernization project, and that didn’t just disappear. Recall that Cisco was hyped to announce its buyout of the Evil Empire’s supercomputer team. Why wasn’t capitalist Russia able to, well, capitalize? You’re already familiar with one of the reasons: The United States absorbed a lot of human capital originally financed by the Soviet people. American immigration policy was based on draining technical talent in particular from the Second World. Sergey Brin is the best-known person in the Moscow-to-Palo-Alto pipeline, but he’s not the only one.

Look at the economic composition of China and Russia in the wake of Soviet dissolution: Both were headed toward capitalist social relations, but they took two different routes. The Russian transition happened rapidly. The state sold off public assets right away, and the natural monopolies such as telecommunications and energy were divided among a small number of skilled and connected businessmen, a category of guys lacking in a country that frowned on such characters but that grew in Gorbachev’s liberalizing perestroika era. Within five years, the country sold off an incredible 35 percent of its national wealth. Russia’s richest ended the century with a full counterrevolutionary reversal of their fortunes, propelling their income share above what it was before the Bolsheviks took over. To accomplish this, the country’s new capitalists fleeced the most vulnerable half of their society. “Over the 1989–2016 period, the top 1 percent captured more than two-thirds of the total growth in Russia,” found an international group of scholars, “while the bottom 50 percent actually saw a decline in its income.” Increases in energy prices encouraged the growth of an extractionist petro-centered economy. Blood-covered, teary, and writhing, infant Russian capital crowded into the gas and oil sectors. The small circle of oligarchs privatized unemployed KGB-trained killers to run “security,” and gangsters dominated politics at the local and national levels. They installed a not particularly well-known functionary—a former head of the new intelligence service FSB who also worked on the privatization of government assets—as president in a surprise move on the first day of the year 2000. He became the gangster in chief.

Vladimir Putin’s first term coincided with the energy boom, and billionaires gobbled up a ludicrous share of growth. If any individual oligarch got too big for his britches, Putin was not beyond imposing serious consequences. He reinserted the state into the natural monopolies, this time in collaboration with loyal capitalists, and his stranglehold on power remains tight for now, despite the outstandingly uneven distribution of growth. Between 1980 and 2015, the Russian top 1 percent grew its income an impressive 6.2 percent per year, but the top .001 percent has maintained a growth rate of 17 percent over the same period. To invest these profits, the Russian billionaires parked their money in real estate, bidding up housing prices, and stashed a large amount of their wealth offshore. Reinvestment in Russian production was not a priority—why go through the hassle when there were easier ways to keep getting richer?

While Russia grew billionaires instead of output, China saw a path to have both. As in the case of Terry Gou, the Chinese Communist Party tempered its transition by incorporating steadily increasing amounts of foreign direct investment through Hong Kong and Taiwan, picking partners and expanding outward from the special economic zones. State support for education and infrastructure combined with low wages to make the mainland too attractive to resist. (Russia’s population is stagnant, while China’s has grown quickly.) China’s entry into the World Trade Organization, in 2001, gave investors more confidence. Meanwhile, strong capital controls kept the country out of the offshore trap, and state development priorities took precedence over extraction and get-rich-quick schemes. Chinese private wealth was rechanneled into domestic financial assets—equity and bonds or other loan instruments—at a much higher rate than it was in Russia. The result has been a sustained high level of annual output growth compared to the rest of the world, the type that involves putting up an iPhone City in a matter of months. As it has everywhere else, that growth has been skewed: only an average of 4.5 percent for the bottom half of earners in the 1978–2015 period compared to more than 10 percent for the top .001 percent. But this ratio of just over 2–1 is incomparable to Russia’s 17–.5 ration during the same period.

Since the beginning of the twenty-first century, certain trends have been more or less unavoidable. The rich have gotten richer relative to the poor and working class—in Russia, in China, in the United States, and pretty much anywhere else you want to look. Capital has piled into property markets, driving up the cost of housing everywhere people want to live, especially in higher-wage cities and especially in the world’s financial centers. Capitalist and communist countries alike have disgorged public assets into private pockets. But by maintaining a level of control over the process and slowing its tendencies, the People’s Republic of China has built a massive and expanding postindustrial manufacturing base.

It’s important to understand both of these patterns as part of the same global system rather than as two opposed regimes. One might imagine, based on what I’ve written so far, that the Chinese model is useful, albeit perhaps threatening, in the long term for American tech companies while the Russian model is irrelevant. Some commentators have phrased this as the dilemma of middle-wage countries on the global market: Wages in China are going to be higher than wages in Russia because wages in Russia used to be higher than wages in China. But Russia’s counterrevolutionary hyper-bifurcation has been useful for Silicon Valley as well; they are two sides of the same coin. Think about it this way: If you’re a Russian billionaire in the first decades of the twenty-first century looking to invest a bunch of money you pulled out of the ground, where’s the best place you could put it? The answer is Palo Alto.

Malcolm Harris, Palo Alto

[lenbryant]

(Long rePost) "Blood in the water"

How SAG-AFTRA strike will create global havoc for Hollywood - Los Angeles Times

SAG-AFTRA members picket outside Netflix in Hollywood on Friday, the first day of the union’s strike — and first such walkout in 43 years.

(Myung Chun / Los Angeles Times)

Hollywood top executives figured they could ride out a skirmish with screenwriters reeling from technology’s changes to the industry.

But few executives were prepared for — or wanted — a strike by the industry’s largest union, SAG-AFTRA, which represents 160,000 actors and other performers. 

After talks over a new contract collapsed last week, throngs of performers joined writers on picket lines — plunging Los Angeles’ signature industry into chaos and further complicating what some fear could become a long and devastating strike.

Movie shoots have ground to a halt. A-list stars have bailed on film and TV marketing campaigns. Matt Damon, Cillian Murphy and other actors walked outduring Thursday night’s London premiere of Universal Pictures’ highly anticipated “Oppenheimer.” 

The upcoming fall TV season could sputter, devoid of new scripted episodes of “Abbott Elementary,” “Law & Order: SVU” and “NCIS.” And media companies that were already struggling to compete in the streaming era could see their fortunes further sink.

“There’s going to be a lot of blood in the water,” Jonathan Taplin, director emeritus of USC’s Annenberg Innovation Lab, said. “This is not going to end well.”

Simultaneous strikes by the Writers Guild of America and the Screen Actors Guild-American Federation of Television and Radio Artists — the first joint work stoppage since Ronald Reagan led SAG in 1960 — couldn’t come at a worse time for traditional entertainment companies.

Their businesses haven’t fully recovered from pandemic shutdowns. Walt Disney Co., Paramount Global and Warner Bros. Discovery have been grappling with heavy debt loads due to mergers, and also from ordering dozens of shows to ramp up their streaming services. All the while, linear broadcast and cable TV networks have witnessed a precipitous slide in viewers to Netflix and other streaming services.

“The economics of the industry are very challenging — the worst that we’ve ever seen,” veteran media analyst Michael Nathanson said. “A prolonged strike will only make things worse.”

Amid a nationwide rise in labor activity, Hollywood’s discord has taken on the trappings of a larger cultural clash, ostensibly pitting everyday workers against top wage earners, America’s 1%. 

On picket lines and social media sites, richly compensated industry leaders, including Disney Chief Executive Bob Iger and Warner Bros. Discovery Chief David Zaslav, are being portrayed as cartoon villains.

Outside Disney’s Burbank headquarters on Friday, a striking worker hoisted a sign that depicted Iger’s face superimposed on a hand-drawn Marie Antoinette figure, holding a raspberry-colored confection under the words: “How about sharing some of that cake, Bob?” 

SAG-AFTRA President Fran Drescher, center, and SAG-AFTRA National Executive Director Duncan Crabtree-Ireland, left, outside Netflix on Friday. 

(Myung J. Chun / Los Angeles Times)

SAG-AFTRA President Fran Drescher, best known for starring in the 1990s sitcom “The Nanny,” has been celebrated among striking workers after her rousing speech Thursday to announce her board’s unanimous vote to call a strike against the Alliance of Motion Picture and Television Producers, the organization that negotiates on behalf of the media companies.

Actors are seeking higher minimum pay, increased residuals and revenue sharing with the streamers. They’ve demanded protections against the use of artificial intelligence to simulate background actors, known as “extras.” Writers have made similar demands, saying since the rise of streaming, midlevel writers have struggled to make a living wage.

“The entire business model has been changed because of streaming, digital and AI,” Drescher said. “At some point, you have to say ‘no, we’re not going to take this anymore.’”

The AMPTP defended the offer the group had made to actors, including what it said was the highest percentage increase in pay minimums in 35 years and a “groundbreaking” proposal for AI protections. 

“A strike is certainly not the outcome we hoped for as studios cannot operate without the performers that bring our TV shows and films to life,” the AMPTP said. “The union has regrettably chosen a path that will lead to financial hardship for countless thousands of people who depend on the industry.”

It’s not clear when bargaining sessions with the actors might resume. No talks are currently scheduled. 

AMPTP negotiators haven’t met with the WGA in more than two months.

Taplin, a former film producer who wrote a book about artificial intelligence, “The End of Reality: How Four Billionaires Are Selling Out Our Future,” said the threat posed by technology “for all artistic production is gigantic.”

“People worry, in the abstract, about AI replacing workers but here it is, it’s actually happening,” Taplin said. “They don’t want to have to pay for extras anymore, so they could have a scene that has 5,000 AI extras in the background.”

Technology also has upset Hollywood’s hierarchy. AMPTP’s shifting makeup now includes tech giants Amazon, Apple and Netflix — companies that don’t have a tradition of collective bargaining.

Veteran executives said the group, even in good economic times, formed an uneasy alliance. Member companies, including Disney, Comcast’s NBCUniversal and Netflix, are more accustomed to battling one another for viewers and revenue. 

And some in Hollywood have wondered whether the AMPTP’s shifting makeup will stand in the way of a deal. 

When reached for comment, AMPTP spokesperson Scott Rowe said: “The companies remain completely united.”

But unlike past strikes, including the 100-day standoff between writers and studios in 2007-2008, no leading executive has emerged to help broker labor peace.

Director Steven Spielberg, left, Disney CEO Bob Iger and director James Cameron in January. 

(Jay L. Clendenin / Los Angeles Times)

Wall Street already has placed its bets, punishing the stocks of legacy media companies. 

Since the writers’ strike began in May, Disney’s stock has fallen 13% to $88.62 a share. Paramount has dropped more than 30% to $15.96 a share, and Warner Bros. Discovery has declined nearly 7% to $12.40. 

Shares of WBD, which owns HBO and CNN, closed at $12.40 on Friday, down nearly 50% since April 2022 when the smaller Discovery absorbed WarnerMedia — a deal that saddled the company with more than $45 billion in debt. 

In contrast, Netflix shares have soared 36% to $441.91 since the writers’ strike began.

Netflix now boasts a higher market value — nearly $200 billion — than Disney, the world’s largest entertainment company, which is valued at $162 billion. 

“Investors are saying Netflix can weather the storm,” Nathanson said. “They make a lot of shows, and stack them up because of the binge-viewing model. They also have a lot more international production that they can import.” 

Disney’s boss, Iger, appeared on business channel CNBC last week from the annual media mogul conference in picturesque Sun Valley, Idaho. The executive, who returned to the company in November, acknowledged that he underestimated the challenges confronting his company — particularly in the traditional television business.

“The disruptive forces that have been preying on that business for a while are greater than I thought,” Iger said. “We have to come to grips with that.”

Disney already has slashed nearly 7,000 jobs this year in an effort to save $5.5 billion. And in a nod to the changing winds, Iger suggested Disney might consider shedding linear channels, perhaps even the ABC television network. 

The company, he said, also is open to taking on a strategic partner for ESPN. 

Disney’s sports empire remains lucrative, but it is plagued by the trend of consumers ditching cable and satellite subscriptions in favor of streaming apps. At some point, the company plans to offer ESPN directly to consumers — but Iger didn’t say when.

“We’re seeing accelerated cord cutting as people are dropping the cable bundle,” Nathanson said. “And advertisers are no longer supporting the networks as they have in the past.” 

Broadcast networks — ABC, CBS, NBC and Fox — are expected to be hit hard by the twin strikes because they are most reliant on fresh programming. Late-night comedians, including ABC’s Jimmy Kimmel and CBS’ Stephen Colbert, have been off the air since early May, when the writers’ strike began.

If the two walkouts are not resolved before October, there probably won’t be any new scripted shows produced until next year, according to company insiders. 

And that could be devastating at a time when traditional networks are struggling to hold on to viewers.

“The networks have sports and news but a lot of their constituents are there to watch the prime-time shows,” said Neil Begley, a senior vice president for Moody’s Investors Service. “Among those viewers, there’s an expectation that fall is the start of the new season. The networks are going to have to reach far and wide for content to fill those hours.”

Compounding matters, this year’s annual TV advertising market, when TV networks sell their commercial time for the new season, has been sluggish.

“Advertisers don’t know what type of programming they’re going to get with these strikes,” Begley said. “They’re saying: Why commit?”

Privately, company executives say their businesses won’t feel much financial pain for several months. Without widespread production, costs will be lower, which translates into higher profits — at least in the short term.

Studios also are expected to begin canceling TV writers’ overall deals to find more savings.

But eventually, networks and streamers will run low on original episodes and media executives will be motivated to reach a detente.

“You can’t get by without actors,” Begley said. “The actors’ strike gave more leverage to the writers.”

Analysts and veteran executives said the market is straining to support all of the streaming services — and shows to stock them — launched in the last five or so years. Hollywood, they say, could look dramatically different after the strikes get resolved.

“Consolidation is going to happen,” predicted Nathanson. “Perhaps the strike will accelerate those moves as the weakness sets in. Some of these players are going to get weaker.”

Times staff writers Richard Verrier, Yvonne Villarreal, Ryan Faughnder, Stephen Battaglio and Anousha Sakoui contributed to this report.

[stanestreet]

Jews around the world have recently celebrated Passover, a festival commemorating the exodus of the Israelites from slavery in ancient Egypt. To mark the occasion, the BBC screened a documentary about a modern exodus, the flight of Jews from France. With an estimated 475,000 Jews, France remains home to Europe’s largest Jewish population. But in recent years, rising anti-Semitism and a series of terror attacks have forced out a growing number. As many as 8,000 left in 2014, up from 1,900 five years earlier, a fourfold increase. Most of them are moving to Israel but many are seeking refuge in Britain. French Jewish children now make up half the intake at Jewish schools in London. Anyone who has travelled recently to Paris will have seen signs of the tense atmosphere that French Jewish refugees are leaving behind. Every Jewish building is guarded by soldiers in full combat gear.

Sadly, anti-Semitism in France is only the starkest manifestation of a growing contemporary Jew-hatred in Europe and across the world. The cancerous belief that the world is run by an international Jewish conspiracy shapes the world-view of much of Iran’s governing elite, operatives of Islamic State (IS), nationalist leaders in Slovakia and Hungary, and a major Palestinian political organisation. It even pervades parts of a mainstream British political party, and our university campuses, too. Where did this poison come from, and is there an antidote to it?

1. European origins

Conventional religious Jew-hatred is thousands of years old. Across the Christian world, the Jews’ claim to be a “chosen people” and the accusation that Jews killed Jesus led to violent persecution. Throughout Europe, anti-Jewish pogroms were sparked by the accusation that Jews kidnapped and killed Christian children in order to use their blood for religious purposes, particularly in unleavened bread consumed on Passover. One of the earliest cases of the blood libel occurred in Norwich in 1144. Within 150 years, the entire Jewish community was expelled from England. Across Europe, Jews were confined to ghettos and restricted to certain professions, such as moneylending, inculcating an image of Jews as nefarious Shylocks.

Most European Jews were emancipated by the mid-19th century. Thereafter, a new brand of paranoid, racial, political anti-Semitism emerged. As feudal systems fell across Europe, Jews were held responsible for the social and cultural ills that accompanied the collapse of the old order. The Jews were viewed as the vanguard of the department store, which ruined small shopkeepers, of the Industrial Revolution, which gave advantage to the few at the expense of the many, and of a global financial system that enslaved economies through the market and its servant parliamentary democracy. It was in response to this new anti-Semitism, and in particular the Dreyfus affair in France, in which a Jewish army officer was falsely accused of treason amid an atmosphere of intense anti-Jewish bigotry, that Theodor Herzl developed modern Zionism – the re-establishment of a Jewish state in the Jews’ ancient homeland.

Adolf Hitler came to anti-Semitism by way of anti-capitalism, particularly of the “international”, Anglo-American variety, which he accused of reducing post-First World War Germany to the status of a “colony”. The socioeconomic decline of the German middle class after the First World War and particularly during the Great Depression helped bring him to power and make the Holocaust possible.

Jew-haters have thus built on different tropes in different contexts and countries. What unites modern anti-Semites, however, is the conspiratorial belief that Jews run the world. Its foundational text is The Protocols of the Elders of Zion. First published in a St Petersburg newspaper in 1903, and subsequently reprinted many times by Russia’s political and religious authorities, this forgery purported to be a blueprint for a secretive scheme to overthrow all existing governments, institutions and religions and, in their place, to construct a Jewish world empire.

The Protocols was neither the first nor the last publication of its kind but it was by far the most successful. After the Russian Revolution, this fabrication was brought to central and western Europe by White Russian émigrés. In the febrile atmosphere across the continent after the First World War, the Protocols offered a simplistic explanation for global unrest. The Jews served as convenient scapegoats for German and Russian right-wingers, seeking to explain their traumatic defeats, and offered an external and internal enemy against whom to rally their countrymen.

Since the Protocols first appeared, millions of copies have been published and the text has been translated into many languages. But nowhere has it been disseminated more widely in the past half-century than in the Islamic world, where political anti-Semitism is a relatively recent phenomenon.

2. Middle Eastern connection

Previously, the Muslim-Jewish relationship was an ambiguous one. While there are verses in Islamic scripture that some have taken as commanding all Muslim believers to kill Jews and Christians, there are also verses urging tolerance towards both.

There were pogroms against Jews in Granada (1066) and Fez (1465) in which thousands were killed. Within the Ottoman empire, however, Jews enjoyed protection as second-class citizens (dhimmis), allowed to practise their religion quietly as long as they paid a special poll tax, abided by various proscriptions, including bans on bearing arms and riding horses, and accepted their inferior status. Up until the 18th century, Jews fared far better in the Muslim world than in Christian Europe.

When anti-Jewish persecution grew more pronounced in the 19th century, responsibility often lay with Christian Arab communities, whose propagation of the European-sponsored blood libel produced the Damascus outrage of 1840 in which 13 leading Jews were arrested and four killed. It was only after the First World War, the Balfour Declaration and the establishment of European protectorates over parts of the former Ottoman empire that growing anti-Zionism provoked violence against Jews across the Arab world. Massacres of Jews occurred in Hebron (1929), Baghdad (1941) and Tripoli (1945). The Grand Mufti of Jerusalem, who resided in Germany for much of the Second World War, urged the Nazis and their allies not to allow Jews to escape to Palestine, but to send them “to Poland” (meaning Auschwitz) instead. Even before the establishment of Israel in 1948, therefore, paranoid, political anti-Semitism had gained a foothold in the Islamic world.

After 1948, anti-Semitism among Arabs was exacerbated by the defeat of their armies by a people traditionally confined to a subservient position in the Muslim world. A tragic consequence of the war was that hundreds of thousands of Palestinian Arabs fled or were expelled and, in response, hundreds of thousands of Jews from across the Arab world, members of 2,000-year-old communities, were now identified as Zionist agents, persecuted and ultimately driven to seek refuge in Israel. The Protocols, which first appeared in Arabic in 1927, and Hitler’s Mein Kampf, partially published in Arabic in the 1930s and fully in 1963, now found even more enthusiastic readers across the region. As the USSR emerged as a political ally of the Arab nations, and the United States forged closer ties with Israel after the 1967 war, Arab anti-Semites increasingly focused on the allegedly capitalist and imperialist character of world Jewry, and on Jewish control over US foreign policy.

In recent decades, this brand of anti-Semitism has become increasingly Islamised. As early as 1950, the seminal Islamist thinker and Muslim Brotherhood leader Sayyid Qutb was writing about “Our Struggle With the Jews”. Qutb claimed that “world Jewry’s purpose is to eliminate all limitations, especially the limitations posed by faith and religion, so that the Jews may penetrate into [the] body politic of the whole world and then may be free to perpetuate their evil designs”. But it was only with the failure of Arab nationalism by the late 1970s that Islamist anti-Semitism really took off.

The founding charter of Hamas, the Sunni Muslim fundamentalist organisation that governs Gaza, refers approvingly to the Protocols and quotes a disputed hadith that says: “The hour of judgment shall not come until the Muslims fight the Jews and kill them, so that the Jews hide behind trees and stones, and each tree and stone will say: ‘O Muslim, o servant of Allah, there is a Jew behind me, come and kill him.’”

The leader of the 1979 Iranian Revolution, Ayatollah Khomeini, declared in his book Islamic Government (1970) that “Jews and their foreign backers are opposed to the very foundations of Islam and wish to establish Jewish domination throughout the world”. Khomeini’s successor, Ayatollah Khamenei, often denies the Holocaust, and he and other Iranian leaders routinely refer to the global dominance of “Jewish” and “Zionist” forces – terms that they use interchangeably.

Iran’s Shia proxy, Hezbollah, has fought to keep Anne Frank’s diary out of Lebanese schools as part of a Holocaust denial campaign and its leader, Hasan Nasrallah, stated that if the Jews “all gather in Israel, it will save us the trouble of going after them worldwide”. However, this did not preclude Hezbollah from targeting a Jewish community centre in Buenos Aires (1994) or bombing Israelis on a bus in Bulgaria (2012).

Even in Malaysia, remote from Israel and home to barely any Jews, anti-Semitism is rife. In 2003 Prime Minister Mahathir Mohamad urged the world’s Muslims to unite against Jews, claiming that although Europeans had killed six million of them, “today the Jews rule the world by proxy”. Just last month, Dr Fouad Bseiso, the Palestine Monetary Authority’s first governor in the 1990s, claimed on Hamas satellite TV that “global Judaism” had caused the 2008 fin­ancial crisis, fulfilling plans revealed in the Protocols. Explicit anti-Semitism is routine in Middle Eastern political discourse. At the same time, this toxic ideology is being reimported into its continent of origin and is now flourishing among disenfranchised Muslim immigrant communities in Europe.

3. The reimportation of anti-Semitism to Europe

The embodiment of this new anti-Semitism is the proudly anti-Zionist and Jew-baiting French “comedian” Dieudonné M’bala M’bala. His shows are particularly popular among disadvantaged French youth from immigrant backgrounds. They feature Holocaust revisionism, jokes about the gas chambers and the “quenelle”, an inverted Hitler salute that M’bala M’bala invented. M’bala M’bala also likes to refer to the Shoah as the “shoannas” (as in ananas), likening the Holocaust to a pineapple. In January, he responded to the killings of Jews at a kosher supermarket in Paris by signalling solidarity with the perpetrator, Amedy Coulibaly.

Coulibaly’s armed assault, two days after the Charlie Hebdo killings, followed a pattern that has long been evident in Islamist terror attacks. In March 2012, Mohamed ­Merah killed seven people in Toulouse. Four of his victims, including three children, were murdered at a Jewish day school. In 2014 Mehdi Nemmouche, a French national of Algerian origin, killed four visitors to the Jewish Museum in Brussels. Security services now view this as the first in a succession of attacks in Europe linked to Islamic State. Nemmouche was part of the European network set up by Abdelhamid Abaaoud, thought to have masterminded the November Paris terror attacks that left 130 dead.

Nor is this pattern evident only in Europe. One target of the 2008 Mumbai terror attacks was a Jewish centre, where hostages were tortured before being killed. After the 19 March suicide bombing in Istanbul, where three of the five victims were Israelis, intelligence offers uncovered advanced plans by IS terrorists to murder Jewish children in Turkey.

What is striking about all these attacks is that they are directed against Jews worldwide, rather than Israel itself. In part, to be sure, this reflects the Jewish state’s capacity to defend itself, but it is also a sign that these anti-Semites see themselves as engaged in a global struggle against Jewry, rather than just a regional contest against Israel.

4. Resurgence of fascist anti-Semitism

Though Islamist anti-Semitism is the most virulent strain of this hatred today, the old-style, fascist variant is also experiencing a revival in Europe. Far-right parties are advancing across the continent and many are directing their hatred against Muslims and Jews alike. Anti-Semitism is very pronounced in Hungary, home to the largest population of Jews in the eastern European Union. Gábor Vona, chairman of the racist Jobbik, which recent opinion polls rate as Hungary’s second-strongest party, told a rally in Budapest against the World Jewish Congress in 2013: “Israeli conquerors, investors and expansionists should look for a country in another part of the world because Hungary is not for sale.” Vona accused Hungarian “Jews” (pure and simple) of being “anti-Hungarian”. A Jobbik MP called on the Hungarian government to “establish how many people of Jewish descent there are here, and especially in the Hungarian parliament and the Hungarian government, who represent a security risk”.

Another manifestation of a far-right movement motivated by anti-Judaism, sometimes masquerading as anti-Zionism, is in Slovakia, home to a minuscule Jewish population since the Holocaust. In March, Marian Kotleba and his ultra-nationalist People’s Party Our Slovakia made a strong showing in parliamentary elections. Until recently, he wore the uniform of the Hlinka Guard – the militia of the Nazi-sponsored Slovak state – which was an eager participant in the transportation of 75,000 Slovakian Jews to the gas chambers. Kotleba’s party newspaper reprinted a Nazi propaganda cartoon featuring a stereotypical image of a Jewish moneylender. This is part of a broad attack on the West and its values. Kotleba has condemned Roma as “gypsy parasites”, denounced Nato as “criminal”, supported Vladimir Putin’s annexation of Crimea and denounced Western democracy for spreading “dangerous sects and sexual deviations”, all standard themes of the far right across Europe.

Like Nazi ideology, Islamist extremism and far-right fascism are rooted in a deep-seated anti-Semitism that begins by targeting Jews and expands its focus outwards. Islamists and European fascists are convinced that a global Jewish conspiracy runs the world. They regard Jews as the embodiment of the West and as symbols of all they most despise about its values: tolerance, liberty, freedom and democratic capitalism. The West is thus regarded as politically “Jewish” whether it is aware of this or not.

Far from being an exclusively Jewish problem, paranoid, political anti-Semitism endangers us all. It is the harbinger of a broader assault on Western modernity.

5. Anti-Semitism and the left

As the heir of the Enlightenment and ideals of the French Revolution, the European left championed emancipation, equality and tolerance in the 19th and early 20th centuries. Thus, it was regarded favourably by Jews. And yet hostility to Jews animated the world-view of some pioneering socialists. For instance, the late-18th- and early-19th-century utopian socialist Charles Fourier regarded Jews as “parasites, merchants, usurers”. They were agents of capitalism and commerce, personified most powerfully by the Rothschilds. Karl Marx, even though he was of Jewish descent, claimed that Jews had made money the “God of the world” and called for humanity to be emancipated from Judaism. It was these manifestations of anti-Judaism that led the German Social Democrat August Bebel to refer to anti-Semitism as the “socialism of fools”.

That Jewish leftists were heavily represented in the leadership of the socialist and communist movement, from Trotsky down, led right-wing racists to equate Judaism with Bolshevism. At first, the Soviet Union embraced this association. In 1931 Stalin declared that anti-Semitism was “the most dangerous vestige of cannibalism” and that “under USSR law . . . active anti-Semites are liable to the death penalty”. The USSR was the first state to grant de jure recognition to Israel, and supported it with arms during the 1948 conflict. However, it turned sharply against Israel and global Jewry from the 1950s onwards.

In the early 1950s, Stalin launched a major anti-Jewish campaign that culminated in the arrest of Jewish doctors accused of poisoning Communist leaders. In 1952, he told the Politburo: “Every Jewish nationalist is the agent of the American intelligence service.” America was the USSR’s principal enemy in the Cold War and its sizeable Jewish community was believed to be at the centre of a worldwide network that was doing the bidding of the new Israeli state, and which had operatives across the globe, including the USSR and communist-controlled eastern Europe.

This anti-Semitic, anti-Zionist campaign was taken up throughout the communist world. Its anti-Jewish nature was clear in the show trials of Jews and their removal from critical positions in local Communist Parties, accompanied by a barrage of openly anti-Semitic propaganda. The most notorious instance of this was the 1952 Slansky trial in Czechoslovakia, during which the state denounced the defendants, not all of whom were Jewish, as “Zionists”, “Jewish capitalists” and “Jewish Gestapo agents”.

After Stalin’s death, his successors upheld his legacy of conspiratorial, anti-Semitic anti-Zionism. Soviet propaganda portrayed “Zionism” as both a tool and a puppet master of US imperialism, peddled the delusion that a state established by Jews fleeing genocidal racism was in fact a Western colonialist enterprise, and depicted “Zionists” as the ideological heirs of Nazi Germany, controlling financial markets and the media. These calumnies were uncritically circulated by the communist press in Europe and seeped into the ideology of Soviet sympathisers on the socialist left. The residue of this can be seen in the former Labour parliamentary candidate Vicki Kirby’s suggestion that Hitler was “the Zionist God” and the Trotskyist former Labour member Gerry Downing’s contention that a capitalist offensive against workers is led by “the Jewish-Zionist bourgeoisie”.

Soviet-sponsored anti-Semitism was reinforced by a third-world romanticism that regarded Zionism as reactionary imperialism and the Arab opponents of Israel as progressive fighters for national liberation who could never be condemned, however radical their rhetoric and tactics.

Western extreme leftists attended Palestinian terror training camps and participated in attacks against Israelis and European Jews. In 1976, operatives from the Popular Front for the Liberation of Palestine and members of the German Revolutionary Cells hijacked an Air France flight and diverted it to Entebbe. They released all non-Jewish passengers and held all Israelis and other Jews of various nationalities hostage.

Conspiratorial leftist, anti-Semitic anti-Zionism did not disappear with the collapse of the USSR. Instead, it mutated into an anti-globalist variant, maintaining the belief that Israel is a vestige of Western colonialism and that “Zionists” are behind the spread of global capitalism, run US foreign policy and seek world domination. The extent to which this poisonous perspective is thriving on British university campuses is illustrated by Malia Bouattia’s election as president of the National Union of Students (NUS). Bouattia has called the University of Birmingham a “Zionist outpost”, on the grounds that it has “the largest J-Soc [Jewish Society] in the country”. While serving as the NUS’s national black students’ officer, she refused to vote for a motion condemning IS and blamed UK anti-terrorism policy on a “Zionist and neocon lobby”.

Further evidence of left-wing anti-Semitism emerged when it was reported that the Labour MP for Bradford West, Naz Shah, until 26 April a PPS to the shadow chancellor, John McDonnell, and a member of a parliamentary select committee investigating British anti-Semitism, had urged the “transportation” of Israeli Jews to America en masse. Shah was consequently suspended from the Labour Party.

Unlike Islamist and far-right extremists, most of the “anti-Zionist” left does not think of itself subjectively as anti-Semitic; many would be appalled at the suggestion. They are often uncomprehending of the nature of Middle Eastern and Islamist anti-Semitism, as evidenced by Vicki Kirby wondering on Twitter why IS had not yet attacked “the real oppressors #Israel”.

One wonders what is more remarkable here: the spectacle of a member of a mainstream Western party handing out white feathers to an extreme Islamist terror group, or her failure to understand that it is primarily waging a global war on Jews and the West, not a regional struggle against Israel. One way or the other, leftist elements who speak of the “Zionist media”, conflate Jews with Israel and generally obsess about Palestine exhibit a structurally anti-Semitic world-view, whether they are conscious of it or not. It is striking that those who spend so much time talking about “discourses”, “dog-whistle politics” and suchlike should show so little sensitivity when it comes to the use of language about Israel, Zionism and the Jews.

All this shows that much of the British student left, and parts of the Labour Party, have “some kind of problem with Jews”, as Alex Chalmers stated when resigning as co-chair of the Oxford University Labour Club in February 2016. A coalition of apparently anti-racist, anti-colonial activists is united in its unwavering hostility to “Zionism”. They demand that Jews and only Jews give up their national self-determination, for the belief in the right to a Jewish state is all that the term “Zionism” means.

The absurdity of anti-racist anti-Semitism is perhaps most clearly demonstrated by a march in 2014 in Toulouse against anti-Semitism, homophobia and other forms of racism that ended in Jewish protesters being denounced as Zionists and urged to leave. When Jews are being chased away from rallies against anti-Semitism, the problem should be clear for all to see.

6. An antidote?

Dealing with anti-Semitism has become more difficult since 1945, after the mass murder of the Holocaust, as few anti-Semites, at least in Europe, are now willing to wear that label openly. Anti-Semitism is a virus that has taken so many forms and proved so resistant that it may be impossible ever to eradicate it. Yet we must begin by recognising that anti-Semitism is a world-view, rather than just another form of prejudice. Other groups – such as black people and gypsies – may suffer worse discrimination in European societies every day. Nobody, however, thinks that black people or gypsies run the world.

After the Charlie Hebdo and kosher supermarket attacks, the BBC correspondent Tim Willcox put it to a terrified Jewish woman that a possible explanation for the slaughter was that “Palestinians suffer hugely at Jewish hands”. Leaving aside that no action taken by Israel could justify the killing of Jews merely because they are Jews – in Paris or anywhere else in the world – it is clear that the murders were motivated not simply by a particular reading of the Israeli-Palestinian conflict but by a paranoid, conspiratorial anti-Semitism.

We must ensure that expressing solidarity for the Palestinian cause does not extend to sharing platforms, joining coalitions or marching in rallies that include anyone who justifies genocidal terrorism, invokes the blood libel or denies the Holocaust. We must reject cultural and moral relativism, and establish a new intellectual and political project committed to combating conspiratorial views of Jewish power, whoever expresses them.

We must make clear that the establishment of the state of Israel was a product of global, especially European, anti-Semitism and not the other way round.

We must recognise that, throughout history, the Jews have served as a “canary in the coal mine”, providing early warnings of extreme, xenophobic ideologies on the rise. This is evident in radical Islamism, the most extreme contemporary manifestation of anti-Semitism. While the West thinks it is fighting a war against “terrorism”, Islamists are fighting a war against what they perceive to be a world Jewish conspiracy. Islamist terror attacks are almost certain to be preceded by, involve, or be followed by attacks on Jews, and we must adjust our ­security measures accordingly.

Above all, we must all be aware of the stakes. Supporting Jewish people worldwide against the new anti-Semitism, be it Islamist, far-rightist or leftist, is not so much a matter of demonstrating solidarity, but of ensuring our own survival.

Although the French government has increased security at Jewish institutions, it is clear that governments alone cannot make Jews feel safe in France or elsewhere in Europe. Moreover, with Dieudonné and his ilk claiming that attacking Jews is the best way to harm the “establishment”, some say that governmental protection only stokes their paranoia. Well, as C P Snow said, the only way to deal with a paranoid man is to give him something to be paranoid about. Other European countries must follow France’s example and devote additional security resources to the defence of Jewish institutions across the continent. They must eschew the example of Belgium, where the authorities asked the Jewish community to drop Purim celebrations, pleading insufficient manpower to protect them after the Brussels attacks in March. The symbolism of the “Great Synagogue of Europe” in the political capital of our continent cancelling service on a major Jewish holiday was shattering.

By dedicating themselves to defending Jewish institutions across the country, the French security authorities have shown that they recognise that paranoid anti-Semitism is a threat to civilised values everywhere. As soon as the rest of the world wakes up to this, and ensures that Jews never again have to flee persecution, the safer we will all be.

[denimbex1986]

'Tom Cruise knows how to sell tickets—even to other people’s movies. “This summer is full of amazing movies to see in theaters,” the Mission: Impossible star wrote on Instagram recently, while he and director Christopher McQuarrie posed with tickets in front of posters for rival films. Cruise congratulated Harrison Ford for “creating one of the most iconic characters in cinema history” with Indiana Jones, and identified himself as one of the many people who’d make a double feature out of Oppenheimer and Barbie, which will go head-to-head in theaters as of July 21. His act of goodwill proved to be contagious, as he must have hoped it would. A few days later, Barbie director Greta Gerwig and star Margot Robbie tweeted their own photo shoot, in which they also waved tickets to their rivals: “Mission: Accepted!”

Summer box office used to be the ultimate showbiz blood sport. Now, publicly at least, it’s all kumbaya and collegiality, which says a lot about the industry’s enduring post-pandemic fears. Beneath the gracious social media shoutouts is a pervasive sense that if the public doesn’t fall back in love with in-person moviegoing for good now, the bottom will continue to fall out of the studio system and take stars down in the process. So far, summer 2023 has proven to be a bumpy ride. Sure-things have struggled, surprise sleepers have failed to emerge, and pressure is mounting on a handful of July titles to save the season.

Box office watchers are still predicting that movies like Mission: Impossible—Dead Reckoning Part One and Barbie can help summer ticket sales in the US and Canada hit $4 billion, which would be taken as a sign that the industry has indeed recovered from an anemic three years. But a trail of early underperformers—including DC’s The Flash, Pixar’s Elemental, and Indy’s fifth and final outing, Indiana Jones and the Dial of Destiny—has only stoked worries. With his cheerleading post, Cruise, the man who “saved Hollywood’s ass” last summer with Top Gun: Maverick, is attempting to stage a rescue mission again. This time he’ll have some help from Barbie and the atomic bomb.

Hollywood power brokers are watching all this closely, to say the least. “I was very excited after Super Mario Bros., and then I got a little more concerned after the last four weeks,” says producer Jason Blum, best known for low-cost horror hits Paranormal Activity, Insidious, and M3GAN. “The movie business has in no way bounced back like the live events business has, but I really think that it’s a matter of time.” Few expect earnings to surpass summer 2019 levels—when 32 films brought in $4.34 billion—but anything close will be a win. The industry is used to absorbing bad news—and hoping for last-minute salvation. “Not everything works,” says another studio executive poring over summer ticket sales, “but that’s just the movie business.”

There are reasons to be at least optimism-adjacent. Moviegoers still want to see spectacle—and they are willing to pay extra to see it on premium large-format screens. “2023 has definitely been a much fuller slate than pre-pandemic times,” says IMAX CEO Richard Gelfond. “And for us, it’s even a little more intense because the audience has shifted more to premium on a global basis. IMAX’s market share went up by 50% in North America and it’s gone up by about 40% globally. So it’s not only more competition within the industry, it’s more competition for IMAX screens. We think our box office will be similar to 2019.”

Similar is the new amazing.

Moviegoers signaled that they were ready to return to theaters last summer when they showed up in droves for Top Gun: Maverick, the top performer of the year with a staggering $719 million in US ticket sales, and Doctor Strange in the Multiverse of Madness, which outperformed 2016’s Doctor Strange. But the robust performance of a handful of titles belied ongoing challenges. Last winter, as one Oscar contender after another died gasping at the box office, a senior awards strategist told Vanity Fair, “the audience is just not there anymore for these sorts of movies.” One obstacle was simply a volume problem: Even though tentpoles like Avatar: The Way of Water were dominating the weekend, there just weren’t enough movies in theaters.

This summer, every weekend offers multiple options, and they’re often aimed at disparate demographics, as with the showdown referred to in some quarters as “Barbenheimer.” Since May 5, when Guardians of the Galaxy Vol. 3 dropped, there’s been a steady beat of new releases, among them The Little Mermaid, Spider-Man: Across the Spider-Verse, and Transformers: Rise of the Beasts. The major studios are expected to release 42 films widely across the country by Labor Day weekend. One studio executive moans about all this in a way that sounds almost nostalgic: “It’s such a crowded summer.”

Before Cruise began his goodwill campaign, the actor was involved in a behind-the-scenes fight for IMAX screens, according to Puck. His latest Mission: Impossible outing will play on IMAX screens for about a week, but then must give them up for Oppenheimer, which debuts a week later on July 21 and has all the screens exclusively booked for three weeks. That has little to do with earnings expectations, and everything to do with relationships. Nolan, a longtime IMAX champion, had struck a deal long before with the exhibitor to guarantee that his movie would play on those screens, regardless of who else parachuted into the market on a motorcycle.

IMAX’s Gelfond tells VF that he worked closely with Nolan and Universal on Oppenheimer’s release date more than a year ago. He visited the Mission: Impossible set and is “a huge fan of Tom’s,” he says, but this is the bottom line: “We made a commitment to Chris. Obviously, I think the movie’s going to be great, but irrespective, we honor our commitments.”

Executives worried about a crowded schedule are one sign that movies are back, baby. “We’ve had really big films since reopening from the pandemic, like Avatar and Top Gun and Spider-Man, but now we’re talking about many titles,” says Elizabeth Frank, the executive in charge of programming AMC Entertainment’s more than 10,000 screens. “People are saying, ‘Well, which one do you want to see first?’ And that’s a different level of excitement. In an industry where momentum is really important, it’s an opportunity for us to build back habitual moviegoing.”

In Hollywood, the weekend box office is treated with the same seriousness as the World Series. “I have a group of friends, we get together at the beginning of the year and we have a draft, we pick all the movies for the year, and points are awarded based on Metacritic score, based on box office, based on awards, and based on profitability,” says Blum, whose company, Blumhouse, has Insidious: The Red Door out on July 7. “We text each other every Thursday or Friday. I’m currently in second place.”

Guys like Blum no doubt pay closer attention to movie ticket sales than the average American, but even he has noticed that more people are following the money as they did years ago. “The box office derby is one of those things that everyone can be a part of,” says Paul Dergarabedian, an entertainment industry analyst for Comscore. “Not everyone has played professional sports or ridden a horse professionally or driven a race car, but we can all sit in a movie theater.”

More scrutiny, of course, means more headlines when movies stumble. For every winner like Guardians of the Galaxy Vol. 3 (with its $356 million in domestic grosses) or Spider Man: Across the Spider-Verse ($346 million), there’s something like The Flash, which has pulled a meager $102 million in the US in spite of its reported $200 million budget, or Elemental, whose $29.6 million debut was considered a major flop for Disney’s Pixar. Meanwhile, Dial of Destiny, which reportedly cost $295 million, arguably needed to make a lot more over Fourth of July than it did. One bright spot? Studios are focusing more on profitability, which Blum contends, “everyone forgot about for about five years.” Now, he says, there’s more pressure to rein in costs: “The budget conversation was the last conversation when you were introducing new projects to buyers. Now it’s the first, which makes me happy because I think less expensive movies are often better and more interesting.”

Even before June gloom hit the box office, Hollywood had largely put its faith in Mission: Impossible, Barbie, and Oppenheimer to carry ticket sales. Now it’s even more imperative that all three titles find their audiences. Early tracking—which pegs the Mission: Impossible opening at around $90 million, Barbie somewhere north of $70 million, and Oppenheimer around $40 million—suggests that they will. Though Ethan Hunt will likely be the biggest star of the summer, media attention has focused squarely on the matchup between Barbie and Oppenheimer.

“I do think a rising tide lifts all boats,” says a top film agent. “When we have pictures in theaters that start to feel like they’re ‘watercooler’—which I really think the Barbie-Oppenheimer thing is becoming—it’s incredibly healthy for the box office, because what we’re doing is delivering an experience that people feel like was worth their time and money.”

AMC has been preparing for the summer movie season by extending operating hours at its theaters, hiring more staff, and making sure its Icee dispensers are full. “Increasingly, fans of different films are also looking for movie-themed merchandise and movie-themed drinks,” says Frank. “It makes the moviegoing experience that much more engaging and dynamic. It’s a little complicated, though, to be moving in the Teenage Mutant Ninja Turtle cups while you’re figuring out whether you’ve still got a bunch of people who want the Mission: Impossible ones or the Barbie ones.”

Predicting the box office has always been like reading tea leaves or tarot cards. Even IMAX’s Gelfond admits to fixating on the returns—from the first night to the last. “Like a junkie,” he says. “I hate to admit it, but yes. Most of our movies open on Thursday nights because they’re big blockbusters. So by Friday morning, I’m on the phone with our distribution and marketing teams trying to understand what the weekend’s going to look like and what’s working and not working and why and why not.”

If you want to know how summer 2023 turns out, you’ll have to wait for the final reel.'

[credenceresearchdotblog]

The Carcinoembryonic Antigen Market is projected to grow from USD 1235 million in 2024 to an estimated USD 3522.944 million by 2032, with a compound annual growth rate (CAGR) of 14% from 2024 to 2032.The global Carcinoembryonic Antigen (CEA) market has been experiencing significant growth, driven by advancements in cancer diagnostics, increased prevalence of cancer worldwide, and the growing awareness of the role of biomarkers in early cancer detection. CEA is a glycoprotein involved in cell adhesion and is commonly used as a tumor marker in cancer diagnostics, particularly for colorectal cancer. This article provides an in-depth analysis of the CEA market, exploring key drivers, restraints, opportunities, and trends shaping its future trajectory.

Browse the full report at https://www.credenceresearch.com/report/carcinoembryonic-antigen-cea-market

Market Definition and Scope

Carcinoembryonic Antigen (CEA) is a biomarker that is frequently measured in blood samples to monitor cancer progression, especially in patients with colorectal, breast, pancreatic, and lung cancers. CEA levels can provide essential insights into cancer recurrence, response to therapy, and prognosis. It plays a crucial role in detecting cancer at an early stage, allowing for timely intervention and personalized treatment plans. The global CEA market encompasses various diagnostic tests, including CEA assays, kits, reagents, and instrumentation.

Key Drivers of the CEA Market

1. Rising Prevalence of Cancer: The increasing incidence of cancer globally is one of the primary factors driving the CEA market. According to the World Health Organization (WHO), cancer is the second leading cause of death worldwide, accounting for approximately 10 million deaths in 2020. Colorectal cancer, in particular, is among the most common cancers, and CEA is widely used in its diagnosis and management.

2. Advancements in Diagnostic Technologies: Technological advancements in diagnostic tools and techniques have improved the accuracy and efficiency of CEA testing. The introduction of highly sensitive immunoassays, such as enzyme-linked immunosorbent assays (ELISAs) and chemiluminescence immunoassays (CLIAs), has enhanced the ability to detect CEA levels in patients, contributing to better cancer management.

3. Growing Demand for Personalized Medicine: As the healthcare industry shifts towards personalized medicine, the demand for biomarkers like CEA is increasing. CEA testing helps in tailoring treatment strategies based on an individual’s tumor biology and response to therapy, improving treatment outcomes and reducing adverse effects.

4. Increasing Awareness and Government Initiatives: Governments and healthcare organizations worldwide are raising awareness about cancer prevention and early detection. In many countries, cancer screening programs that include CEA testing are being implemented to identify high-risk populations. This has further propelled the demand for CEA diagnostic tests.

Challenges and Restraints

1. Limited Specificity of CEA Testing: One of the primary limitations of CEA as a biomarker is its lack of specificity. Elevated CEA levels can also be observed in non-cancerous conditions such as smoking, liver disease, and inflammatory conditions. This can lead to false-positive results, complicating the diagnostic process. Consequently, CEA testing is often used in conjunction with other diagnostic tools to improve accuracy.

2. High Cost of Advanced Diagnostic Tools: The cost associated with advanced diagnostic technologies, including CEA assays, can be prohibitive for healthcare providers, especially in low- and middle-income countries. This limits the accessibility of CEA testing in certain regions, thereby restricting market growth.

3. Regulatory and Reimbursement Challenges: Regulatory approval processes and reimbursement policies for diagnostic tests vary significantly across regions. Stringent regulations and the absence of uniform reimbursement policies can hinder market growth, particularly for new entrants.

Opportunities in the CEA Market

1. Emerging Markets: Developing countries, particularly in Asia-Pacific, are witnessing a surge in healthcare infrastructure development and cancer awareness programs. These regions present significant opportunities for market expansion as healthcare providers invest in advanced diagnostic tools, including CEA testing.

2. Integration of Artificial Intelligence (AI): The integration of AI and machine learning in diagnostic tools offers promising opportunities for the CEA market. AI-powered algorithms can enhance the interpretation of CEA test results, leading to more accurate and timely diagnoses.

3. Collaboration Between Key Players: Collaborations between pharmaceutical companies, diagnostic laboratories, and research institutions can accelerate the development of innovative CEA tests and assays. Such partnerships can also help in overcoming challenges related to regulatory approvals and market penetration.

Market Segmentation

The CEA market can be segmented based on product type, application, and end-user. Product types include CEA assays, kits, reagents, and instruments. Applications of CEA testing are primarily in colorectal cancer, followed by breast, pancreatic, and lung cancers. Key end-users of CEA testing products are hospitals, diagnostic laboratories, and research institutions.

Competitive Landscape

Several key players dominate the CEA market, including Abbott Laboratories, F. Hoffmann-La Roche AG, Siemens Healthineers, and Thermo Fisher Scientific. These companies focus on product innovation, partnerships, and geographic expansion to maintain a competitive edge. For instance, Roche’s Elecsys CEA assay is a popular product in cancer diagnostics, offering high precision and reliability.

Key Player Analysis:

Abbott (U.S.)

Aviva Systems Biology Corporation

Boster Biological Technology (U.S.)

Cigna (U.S.)

Correlogic Systems, Inc. (Hong Kong)

Creative Diagnostics (U.S.)

Hoffmann-La Roche Ltd (Switzerland)

Genway Biotech, LLC. (U.S.)

Laboratory Corporation of America Holdings (U.S.)

Lee BioSolutions (U.S.)

Mayo Foundation for Medical Education and Research (MFMER) (U.S.)

Merck KGaA (Germany)

Omega Diagnostics Group PLC (U.K.)

Prospec-Tany Technogene Ltd (Israel)

Quest Diagnostics Incorporated (U.S.)

RayBiotech Life, Inc (U.S.)

Segmentation:

By Type,

Serum CEA

Tissue CEA.

By Gender,

Male

Female

By Product,

Kits,

Reagents,

Instruments

By Test,

Clinical testing

Research testing.

By End-Use,

Hospitals,

Diagnostic laboratories,

Research institutes.

By  Region

North America

The U.S

Canada

Mexico

Europe

Germany

France

The U.K.

Italy

Spain

Rest of Europe

Asia Pacific

China

Japan

India

South Korea

South-east Asia

Rest of Asia Pacific

Latin America

Brazil

Argentina

Rest of Latin America

Middle East & Africa

GCC Countries

South Africa

Rest of Middle East and Africa

Browse the full report at https://www.credenceresearch.com/report/carcinoembryonic-antigen-cea-market

About Us:

Credence Research is committed to employee well-being and productivity. Following the COVID-19 pandemic, we have implemented a permanent work-from-home policy for all employees.

Contact:

Credence Research

Please contact us at +91 6232 49 3207

Email: sales@credenceresearch.com

Website: www.credenceresearch.com

[marketresearchintent]

Blood Group Typing Market Analysis: New Opportunities in the Healthcare Sector

The Blood Group Typing Market is expected to grow at a rapid pace over the coming years. In 2023, the market was valued at USD 1.9 billion, and by 2030, it's projected to surpass USD 3.3 billion, growing at a compound annual growth rate (CAGR) of 8.2%. This surge in market value highlights the increasing demand for blood typing in various healthcare sectors.

What is Blood Group Typing?

Blood group typing is the process of determining an individual's blood group, typically classified into A, B, AB, or O types. This crucial medical procedure ensures compatibility for blood transfusions, organ transplants, and managing pregnancies where blood group incompatibility may lead to complications. It also plays an important role in research, diagnostics, and therapeutics.

Why is the Blood Group Typing Market Growing?

Several factors contribute to the rapid growth of the blood group typing market:

Rising Demand for Blood Transfusions: The growing number of surgeries and trauma cases has driven the need for safe and compatible blood transfusions.

Advancements in Technology: With the advent of advanced testing technologies, blood typing has become quicker and more accurate.

Increasing Prevalence of Chronic Diseases: As chronic diseases like cancer and cardiovascular conditions become more common, the need for blood transfusions, organ transplants, and diagnostic tests rises.

Government Initiatives: Government health agencies across the globe are launching campaigns to improve healthcare infrastructure, which includes better access to blood banks and safe transfusion practices.

Access Full Report @ https://intentmarketresearch.com/latest-reports/blood-group-typing-market-3123.html  

Key Segments of the Blood Group Typing Market

1. Based on Products

Consumables: Reagents, anti-sera, and red blood cells that are essential for blood typing procedures.

Instruments: Machines used in hospitals and laboratories for blood typing tests.

Services: Outsourcing services for hospitals and laboratories to perform blood group testing.

2. Based on Test Type

Antibody Screening: Detects antibodies in the blood that may cause immune reactions.

HLA Typing: Human leukocyte antigen typing is often used in organ transplantation to ensure compatibility.

ABO Blood Group Typing: The most common test, determining whether a person has blood type A, B, AB, or O.

Crossmatching: Ensures compatibility between donor and recipient blood before a transfusion.

3. Based on Technique

PCR-Based Testing: Polymerase chain reaction (PCR) testing is becoming popular due to its accuracy in detecting rare blood types.

Microarray Testing: A cutting-edge technique that offers detailed insights into blood group antigens.

Gel Agglutination: A traditional method where blood cells clump together to reveal their type.

4. Based on End-User

Hospitals and Clinics: The largest users of blood typing services, especially in emergency care, surgeries, and transfusions.

Blood Banks: Critical for maintaining safe blood supplies for hospitals and clinics.

Diagnostic Laboratories: Play a key role in providing accurate blood typing for various medical needs.

Research Institutes: Blood typing is essential in biomedical research and the development of new medical treatments.

Geographical Insights into the Blood Group Typing Market

North America

North America dominates the global blood group typing market, thanks to its advanced healthcare infrastructure and high demand for blood transfusions. The U.S. leads the region with significant investments in healthcare research and technological advancements.

Europe

Europe holds the second-largest market share, driven by increased demand for organ transplants and blood donations. Countries like Germany, the UK, and France are key players in the region.

Asia-Pacific

Asia-Pacific is the fastest-growing market, with a rapidly improving healthcare infrastructure, especially in countries like China, India, and Japan. Increased government initiatives and rising awareness of safe blood transfusion practices are fueling growth in this region.

Latin America and the Middle East

These regions are experiencing moderate growth, with improving healthcare systems and increased focus on safe transfusion practices. Brazil, Saudi Arabia, and the UAE are emerging as key markets.

Download Sample Report @ https://intentmarketresearch.com/request-sample/blood-group-typing-market-3123.html 

Technological Advancements in Blood Group Typing

Technological innovations have dramatically improved the accuracy and speed of blood group typing. Some of the most noteworthy advancements include:

Automation: Automated blood typing machines reduce human error and streamline the testing process.

DNA-Based Testing: Genetic testing methods like PCR and next-generation sequencing (NGS) have made it easier to identify rare blood types.

Artificial Intelligence: AI-driven platforms can now analyze blood typing data more efficiently, predicting rare blood types and crossmatching results with greater precision.

Challenges in the Blood Group Typing Market

Despite its rapid growth, the blood group typing market faces several challenges:

High Cost of Advanced Technologies: While innovative testing methods improve accuracy, they also raise costs, limiting access in some regions.

Limited Awareness in Low-Income Countries: In developing countries, there is still a lack of awareness regarding the importance of safe blood transfusions.

Regulatory Hurdles: Compliance with government regulations varies by region, sometimes slowing the approval process for new technologies.

Key Players in the Blood Group Typing Market

Several companies are leading the charge in the global blood group typing market:

Bio-Rad Laboratories: Specializing in diagnostics and testing solutions.

Grifols: A global leader in plasma-derived medicines and transfusion diagnostics.

Ortho Clinical Diagnostics: A top player in immunohematology and blood typing products.

Immucor: Focuses on improving transfusion and transplantation diagnostics.

Future Outlook of the Blood Group Typing Market

The future of the blood group typing market looks promising, with continued growth expected through 2030. Some key trends include:

Increased Investment in R&D: Research into advanced blood typing methods will likely continue, focusing on automation, accuracy, and cost reduction.

Emerging Markets: Countries with developing healthcare systems are investing in better blood typing technologies, creating new growth opportunities.

Personalized Medicine: The rise of personalized treatments will likely drive demand for more precise blood typing methods to ensure compatibility in therapies like immunotherapy and gene editing.

Conclusion

The global blood group typing market is on a path of exponential growth, driven by technological advancements, rising demand for blood transfusions, and government initiatives. With the market projected to surpass USD 3.3 billion by 2030, the future looks bright for companies and healthcare providers in this field. As the industry continues to innovate, the accuracy and accessibility of blood group typing will only improve, saving more lives and ensuring safer medical procedures.

FAQs

What is the CAGR of the blood group typing market from 2024 to 2030? The market is expected to grow at a CAGR of 8.2% during this period.

What is the importance of blood group typing? Blood group typing ensures compatibility for blood transfusions, organ transplants, and other medical procedures, reducing the risk of complications.

Which regions are leading the blood group typing market? North America holds the largest market share, followed by Europe and the rapidly growing Asia-Pacific region.

What are the major technologies used in blood group typing? Key technologies include PCR-based testing, microarray testing, and gel agglutination methods.

What are the major challenges facing the blood group typing market? Challenges include the high cost of advanced technologies, limited awareness in developing regions, and regulatory hurdles.

About Us

Intent Market Research (IMR) is dedicated to delivering distinctive market insights, focusing on the sustainable and inclusive growth of our clients. We provide in-depth market research reports and consulting services, empowering businesses to make informed, data-driven decisions.

Our market intelligence reports are grounded in factual and relevant insights across various industries, including chemicals & materials, healthcare, food & beverage, automotive & transportation, energy & power, packaging, industrial equipment, building & construction, aerospace & defense, and semiconductor & electronics, among others.

We adopt a highly collaborative approach, partnering closely with clients to drive transformative changes that benefit all stakeholders. With a strong commitment to innovation, we aim to help businesses expand, build sustainable advantages, and create meaningful, positive impacts.

Contact Us

sales@intentmarketresearch.com

US: +1 463-583-2713

[tamanna31]

Blood Screening Market 2023- Business Planning Research and Resources, Revenue, and Forecasts 2030

Blood Screening Market Size & Trends

The global blood screening market size was valued at USD 2.76 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 11.7% from 2023 to 2030. 

Blood screening is a process in which donated blood is screened for infectious diseases such as HBV, HCV, HIV1, and HIV2. The high growth of this market is attributed to rising blood donations, an increase in the incidence of infectious diseases, and government initiatives. According to World Health Organization (WHO), 118.54 million blood donations are collected yearly. In the U.S., 6.8 million individuals donate blood annually, and 13.6 million units of red blood cells and whole blood are collected annually.

Gather more insights about the market drivers, restrains and growth of the Blood Screening Market

The market is primarily driven by the rise in the rate of disorders such as HIV, diphtheria, measles and chronic diseases such as hemophilia, cancer, and other blood-related disorders. Blood-based diagnostics are used to diagnose a wide range of diseases, including infectious diseases, cancer, and cardiovascular diseases. Serology tests detect the presence of antibodies to a specific disease-causing organism. These tests diagnose various infectious diseases, including HIV, hepatitis B, and syphilis. Molecular tests detect the presence of DNA or RNA from a specific disease-causing organism. These tests are more sensitive than serology tests and can be used to diagnose diseases at an earlier stage. Biochemical tests measure the levels of certain substances in the blood. These tests can diagnose a wide range of diseases, including diabetes, kidney disease, and liver disease.

The COVID-19 pandemic had a significant impact on the market. Although respiratory droplets are the primary means of COVID-19 virus transmission, research has shown that viral RNA may be discovered in blood samples, supporting blood screening for COVID-19 identification, hence driving the market significantly. 

Blood Screening Market Segmentation

Grand View Research has segmented the global blood screening market based on technology, product, and region:

Technology Outlook (Revenue, USD Million, 2018 - 2030)

Nucleic Acid Amplification Test (NAT)

ELISA

Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)

Next Generation Sequencing

Western Blotting

Product Outlook (Revenue, USD Million, 2018 - 2030)

Reagent

Instrument

Regional Outlook (Revenue, USD Million, 2018 - 2030)

North America

US

Canada

Europe

UK

Germany

France

Italy

Spain

Sweden

Norway

Denmark

Asia Pacific

Japan

China

India

Australia

Thailand

South Korea

Latin America

Brazil

Mexico

Argentina

Middle East and Africa

Saudi Arabia

South Africa

UAE

Kuwait

Browse through Grand View Research's Medical Devices Industry Research Reports.

The global embolic protection devices market size was valued at USD 612.9 million in 2023 and is projected to grow at a CAGR of 8.7% from 2024 to 2030. 

The global covered stent market size was estimated at USD 1.13 billion in 2023 and is projected to grow at a CAGR of 4.1% from 2024 to 2030. 

Key Companies & Market Share Insights

Product launches, approvals, strategic acquisitions, and innovations are just a few of the important business strategies used by market participants to maintain and grow their global reach.

For instance, in March 2023, Abbott received U.S Food and Drug Administration (FDA) clearance for a laboratory traumatic brain injury blood test, the first commercially available lab-based test for the assessment of mild traumatic brain injuries (TBIs), commonly referred to as concussions, which will be made widely available to hospitals across the U.S. This test, which is powered by Abbott’s Alinity i laboratory tool, will enable clinicians to evaluate individuals with mild traumatic brain injuries in a timely manner.

Furthermore, in May 2023, Siemens Healthcare introduced Atellica HEMA 570 and 580 next-generation hematology analyzers, which have user-friendly interfaces and can be connected to multiple analyzers to remove workflow barriers and provide high throughput time.

Key Blood Screening Companies:

Abbott

Danaher Corporation (Beckman Coulter)

Becton Dickinson and Company

Bio-Rad Laboratories, Inc.

Hoffman-La Roche Ltd.

Grifols, S.A.

Ortho-Clinical Diagnostics, Inc.

Siemens Healthcare GmbH

Thermo Fisher Scientific, Inc.

SOFINA s.a (Biomerieux)

Order a free sample PDF of the Blood Screening Market Intelligence Study, published by Grand View Research. 

[creativeera]

DNA and RNA Sample Preparation Market is Estimated to Witness High Growth Owing to Increasing Adoption

The DNA and RNA sample preparation market involves processes associated with isolation, extraction, purification and quantification of nucleic acids DNA and RNA from various sources like tissues, blood, sperm, cells etc. for downstream applications in genomics, molecular diagnostics, personalized medicine and others. The sample preparation is a critical and initial step before conducting various genomic tests including Next Generation Sequencing, polymerase chain reaction and other assays. Growing awareness and adoption of precision medicine and genetic/molecular testing is driving demand for efficient nucleic acid isolation and downstream analysis.

The Global DNA and RNA Sample Preparation Market is estimated to be valued at US$ 2262.46 Mn in 2024 and is expected to exhibit a CAGR of 5.8% over the forecast period 2024 To 2031. Key Takeaways Key players operating in the DNA and RNA sample preparation are Agilent Technologies, Inc., Becton, Dickinson and Company, Bio-Rad Laboratories Inc., DiaSorin S.p.A, F. Hoffmann-La Roche, Miroculus, Inc., Illumina, Inc., PerkinElmer, Inc., QIAGEN, Sigma Aldrich Corp., Tecan Group AG, and Thermo Fisher Scientific, Inc. Growing prominence of personalized medicine is creating opportunities for development of new sample preparation methods and kits which can extract nucleic acids from various types of samples. Rising incidence of chronic and infectious diseases worldwide is increasing diagnostic testing which will propel sample preparation market growth. Global expansion of key market players through acquisitions and partnerships with regional diagnostic labs and research institutes will further augment market revenues. Market Drivers Increasing funding for Genomic and genetic research from government bodies as well as private sector is one of the key factors driving the DNA and RNA Sample Preparation Market Size. Government initiatives aimed at large scale population screening and clinical testing for various genetic disorders, infectious diseases and cancers are also creating demand for high throughput nucleic acid preparation. Growing geriatric population and rising healthcare spending in developing nations also provides growth opportunities for market players in the forecast period.

PEST Analysis Political: Laws and regulations imposed by governments for research using DNA and RNA samples could impact the market. Changes in healthcare policies will also have effects. Economic: Factors like GDP growth, income levels, healthcare spending will drive demand. Rise in research activities and focus on precision medicine boost the market. Social: Growing awareness about personalized medicine and importance of genetic testing are important. Social trends also promote preventive healthcare and wellness. Technological: Advancements in fields like next generation sequencing, lab automation, bioinformatics are key for market growth. Miniaturization and portability of equipment expand applications. Developments in sample collection and storage methods improve efficiency. Geographical regions where the market in terms of value is concentrated include North America and Europe. North America accounts for the largest share in the global market due to presence of well-established healthcare industry and research institutes. Europe also captures notable share due to growing biotech sector and research funding. The Asia Pacific region is projected to be the fastest growing market during the forecast period. This is attributed to factors such as increasing healthcare expenditure, growing awareness, expanding biotech industry and rising government investments in research. Countries like China, India offer growth opportunities as they focus on healthcare infrastructure development.

Get more insights on DNA And RNA Sample Preparation Market

Also read related article on Surgical Robots Market

Discover the Report for More Insights, Tailored to Your Language

French

German

Italian

Russian

Japanese

Chinese

Korean

Portuguese

Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.

(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)

[colinwilson11]

Soft Tissue Sarcoma Market To Grow Significantly Due To Increasing R&D Investment By Key Players

The soft tissue sarcoma market is a rapidly emerging field owing to increasing R&D investment by key players. Soft tissue sarcomas are rare cancers that develop in supporting or connective tissues like fat, muscle, blood vessels, deep skin tissues, and nerves. Some of the common types include gastrointestinal stromal tumors, uterine sarcomas, and rhabdomyosarcoma.

Soft tissue sarcomas account for about 1% of all adult cancers. While surgery is the mainstay for treatment of localized disease, advanced cases often require chemotherapy and targeted drug therapy.

The Soft Tissue Sarcoma Market is estimated to be valued at US$ 315 Mn in 2024 and is expected to exhibit a CAGR of 4.2% over the forecast period 2024-2031.

Key Takeaways

Key players operating in the soft tissue sarcoma market are Pfizer, Eli Lilly, Johnson & Johnson, GSK (GlaxoSmithKline), and Roche.

The growing incidence of soft tissue sarcoma cases globally is a major factor driving market growth. Soft tissue sarcomas affected over 13,000 individuals in the United States in 2020 according to statistics.

Technological advancements like targeted drug therapy and development of biomarker assays are expanding treatment options and improving clinical outcomes for soft tissue sarcoma patients.

Market Trends

Increased focus on personalized medicine - Researchers are investigating molecular diagnostic tests and targeted therapies customized to a patient's tumor genetics which may improve response rates.

Combination therapy gaining traction - Combining drugs that work through different mechanisms is a promising approach and ongoing studies are evaluating combinations of chemotherapy with immunotherapies.

Market Opportunities

Immunotherapy emerging as a viable treatment option - Drugs that activate the immune system like checkpoint inhibitors have shown survival benefits in certain sarcoma subtypes creating new opportunities.

Companion diagnostics can guide therapy selection - Development of reliable biomarkers can help identify patients likely to respond to specific therapies and avoid treatment toxicity.

Impact Of COVID-19 On Soft Tissue Sarcoma Market Growth

The COVID-19 pandemic has significantly impacted the soft tissue sarcoma market. During the initial phases of the pandemic in 2020, most hospitals and clinics shifted their focus towards COVID care, which led to postponement of non-emergency surgeries and treatments. This impacted the diagnosis and treatment rates of soft tissue sarcomas. Patients also delayed their appointments and screenings fearing exposure to the virus in healthcare settings. This interrupted the continuity of care and follow-ups, posing challenges to sarcoma management. However, with increased availability of COVID vaccines and resumption of healthcare services from 2021, the market is slowly recovering. There is pent-up demand for diagnostic tests and treatments that were delayed during the peak pandemic phases. Hospitals have implemented strict safety protocols to reassure patients and ensure continuity of sarcoma management. Telehealth and home care services also aided in reducing disruption during lockdowns. Still, workforce shortages in the healthcare sector continue to pose operational difficulties. The long-term impact of delayed diagnoses and treatments remains to be seen. Market players are focusing on improving access to therapies through innovative drug delivery mechanisms and digital solutions.

Geographical Regions With Highest Soft Tissue Sarcoma Market Value

In terms of value, North America dominated the soft tissue sarcoma market as of 2021, owing to established healthcare infrastructure, high adoption of advanced diagnostic tools and therapies, and presence of key market players in the US and Canada. Within the region, the United States accounted for the major share. Europe is another prominent regional market, led by countries like Germany, United Kingdom, France, and others. Growing research on targeted therapies and partnerships between drug makers and cancer institutes are driving market growth across Europe. The Asia Pacific region is poised to be the fastest growing soft tissue sarcoma market over the forecast period due to rising healthcare expenditure, large patient population, and increasing awareness.

Fastest Growing Region For The Soft Tissue Sarcoma Market

The Asia Pacific region holds immense growth potential for the soft tissue sarcoma market and is expected to be the fastest growing region between 2024- 2031. This is attributed to factors like increasing healthcare access and spending in populous countries like China and India, rising incidence of sarcomas accompanying aging demographics, and improving diagnostic infrastructure. Furthermore, growing collaborations between global pharmaceutical companies and regional market players are boosting availability of advanced treatment options. Initiatives to spread awareness about rare cancers are also propelling regional growth. With economic expansion and growing focus on non-communicable diseases, the soft tissue sarcoma market is poised for strong growth across Asia Pacific.

Get more insights on this topic:  https://www.trendingwebwire.com/soft-tissue-sarcoma-market-is-estimated-to-witness-high-growth-owing-to-rising-rd-investments-in-immunotherapy/

About Author:

Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)

What Are The Key Data Covered In This Soft Tissue Sarcoma Market Report?

:- Market CAGR throughout the predicted period

:- Comprehensive information on the aspects that will drive the Soft Tissue Sarcoma's growth between 2024 and 2031.

:- Accurate calculation of the size of the Soft Tissue Sarcoma and its contribution to the market, with emphasis on the parent market

:- Realistic forecasts of future trends and changes in consumer behaviour

:- Soft Tissue Sarcoma Industry Growth in North America, APAC, Europe, South America, the Middle East, and Africa

:- A complete examination of the market's competitive landscape, as well as extensive information on vendors

:- Detailed examination of the factors that will impede the expansion of Soft Tissue Sarcoma vendors

FAQ’s

Q.1 What are the main factors influencing the Soft Tissue Sarcoma?

Q.2 Which companies are the major sources in this industry?

Q.3 What are the market’s opportunities, risks, and general structure?

Q.4 Which of the top Soft Tissue Sarcoma companies compare in terms of sales, revenue, and prices?

Q.5 Which businesses serve as the Soft Tissue Sarcoma’s distributors, traders, and dealers?

Q.6 How are market types and applications and deals, revenue, and value explored?

Q.7 What does a business area’s assessment of agreements, income, and value implicate?

*Note: 1. Source: Coherent Market Insights, Public sources, Desk research 2. We have leveraged AI tools to mine information and compile it

[prognosysmedicalsystems]

Future Trends in X-Ray Technology: What’s Next? - An Article by Prognosys Medical System

X-ray technology has undergone remarkable advancements since its discovery in the late 19th century, transforming from rudimentary imaging systems to highly sophisticated diagnostic tools. As we move further into the digital age, the field of radiology continues to evolve, driven by emerging technologies and a growing demand for more precise, efficient, and patient-centered care. This article explores the future trends in X-ray technology, highlighting innovations that are shaping the future of medical imaging.

1. Artificial Intelligence (AI) Integration: AI is set to revolutionize X-ray imaging by enhancing the diagnostic capabilities of radiologists. AI algorithms are increasingly being integrated into imaging systems to assist in reading X-rays, detecting abnormalities, and providing more accurate diagnoses. Machine learning models trained on vast datasets can identify patterns and anomalies that may be missed by the human eye, leading to earlier detection of conditions such as cancer, fractures, or lung diseases.

For instance, AI-driven software can analyze chest X-rays to screen for signs of COVID-19, tuberculosis, or pneumonia with high accuracy. In addition to improving diagnostic precision, AI can also help reduce the workload on radiologists by automating routine tasks, enabling faster image interpretation and reporting.

According to recent Study done by Straits Research shows that the global AI-enabled X-Ray imaging solutions market size was valued at USD 387.4 million in 2023. It is estimated to reach USD 2,218.11 million by 2032, growing at a CAGR of 21.60% during 2024-2032.

2. 3D and 4D X-Ray Imaging: Traditional 2D X-rays provide valuable information, but they often lack the depth required for complex diagnoses. Enter 3D and 4D imaging, which offer a more detailed view of anatomical structures. 3D X-ray technology, such as Cone Beam Computed Tomography (CBCT), is already being used in dental and orthopedic applications. This allows for more precise visualization of bones and teeth, facilitating accurate surgical planning and treatment.

4D X-ray imaging takes this a step further by incorporating the dimension of time, allowing for real-time visualization of moving body parts. This is particularly useful in dynamic studies such as cardiac imaging, where the movement of the heart and blood vessels can be observed and analyzed in detail.

According to recent Study done by Future Market Insights, Inc. shows that the global advanced (3D/4D) visualization systems market is anticipated to witness an increase in revenue from US$ 731.7 million in 2023 to US$ 1,139.9 million by 2028 which indicates the 3D and 4D X-Ray Imaging systems growth in coming years.

3. Low-Dose and Ultra-Low Dose Imaging: As concerns about radiation exposure continue to grow, the development of low-dose and ultra-low dose X-ray systems is a top priority. Advanced image processing techniques and detector technologies are enabling manufacturers to significantly reduce radiation doses without compromising image quality.

The advent of low-dose systems is especially important in pediatric imaging and for patients requiring multiple scans over time, such as those undergoing cancer treatment. These systems ensure patient safety while maintaining diagnostic accuracy, addressing a key challenge in the widespread use of X-rays in healthcare.

4. Portable and Point-of-Care X-Ray Systems: Portability is a critical trend in medical technology, and X-ray systems are no exception. Mobile and handheld X-ray units are becoming more compact, lightweight, and efficient, allowing for greater flexibility in imaging patients in various settings. Portable X-rays are especially useful in emergency rooms, intensive care units (ICUs), and for bedside imaging in hospitals.

Point-of-care X-ray systems enable immediate diagnosis and treatment, minimizing delays in patient care. In disaster zones or rural areas where access to medical facilities is limited, portable X-ray units can play a vital role in delivering life-saving care.

 In July 2022, MIOT hospital, based in Chennai, India, acquired mobile full-body CT scan equipment to allow real-time imaging during surgeries. Thus, the increase in the adoption of point-of-care imaging technology by end-users. Which shows the Portable and Point-of-Care X-Ray Systems adoption trends.

5. Spectral Imaging and Photon-Counting Detectors: Spectral imaging, also known as dual-energy X-ray imaging, is a rapidly emerging technology that provides enhanced image contrast by capturing multiple energy levels of X-rays. This technique allows for better differentiation of tissues and materials, offering more detailed insights into soft tissue, bone, and even foreign objects.

Photon-counting detectors, another innovation in X-ray technology, improve image resolution and contrast by counting individual photons rather than measuring the overall energy absorbed. This leads to clearer, more detailed images while further reducing radiation exposure. These detectors are expected to become integral components of next-generation CT scanners and X-ray systems.

6. Teleradiology and Cloud-Based Imaging: As healthcare becomes more connected, the need for efficient image sharing and collaboration has grown. Teleradiology, the practice of transmitting radiological images from one location to another for diagnosis and consultation, is already widely used. However, advancements in cloud-based imaging platforms are set to take this to the next level.

Cloud technology allows radiologists and clinicians to access and interpret images remotely in real time, improving workflow efficiency and enabling faster decision-making. These systems also offer secure storage, easy retrieval, and seamless sharing of images across multiple healthcare facilities, ensuring better coordination of care.

7. Hybrid Imaging Systems: Hybrid imaging, which combines two or more imaging modalities into a single system, is gaining traction in the medical field. X-ray/CT hybrid systems, for example, provide the benefits of both conventional X-rays and computed tomography, delivering high-resolution images with the added detail of cross-sectional views.

Such systems are particularly valuable in complex cases where a more comprehensive view of the anatomy is needed. Hybrid imaging enhances diagnostic accuracy, reduces the need for multiple scans, and minimizes patient exposure to radiation by consolidating procedures.

Conclusion The future of X-ray technology is poised for significant transformation, driven by advances in AI, 3D and 4D imaging, portable systems, and spectral imaging. These trends are not only enhancing the accuracy and efficiency of diagnostic imaging but also improving patient safety and care. As these technologies continue to evolve, X-ray systems will become even more integral to healthcare, offering unprecedented opportunities for early detection, precision treatment, and better patient outcomes.

The fusion of innovation and medical imaging holds the promise of a brighter future for radiology and diagnostics.

Click the links to Know More about Prognosys Medical Systems Radiology Product Range.

Contact us for more information:

– Content Team Prognosys Medical Systems

marketing@prognosysmedical.com

[shubhampawrainfinium]

"From Patient to Lab: The Critical Path of Biological Sample Collection Kits"

Market Overview and Report Coverage

The biological sample collection kits market is experiencing significant growth, driven by advancements in medical research, diagnostics, and personalized medicine. These kits are essential for collecting, preserving, and transporting biological samples, including blood, saliva, urine, and tissue samples, for various tests and analyses. The rising prevalence of chronic diseases, growing demand for early disease detection, and advancements in genomic research are key factors propelling the market.

According to Infinium Global Research, the global biological sample collection kits market is expected to grow substantially from 2023 to 2030. The increasing focus on personalized medicine and the expansion of research and development activities in biotechnology and pharmaceutical industries are major drivers of this growth. Additionally, the ongoing COVID-19 pandemic has highlighted the importance of efficient sample collection and testing, further boosting market demand.

Market Segmentation

By Type:

Blood Collection Kits: These kits are used for collecting blood samples for various tests, including routine blood tests, molecular diagnostics, and blood bank screening. They typically include blood collection tubes, needles, and anticoagulants to preserve sample integrity.

Urine Collection Kits: Urine collection kits are used for analyzing urine samples to diagnose conditions such as urinary tract infections, kidney disorders, and diabetes. They include containers, preservatives, and sometimes specialized tests for detecting specific analytes.

Saliva Collection Kits: Saliva collection kits are increasingly popular for genetic testing, hormonal analysis, and drug testing. They are designed to collect and preserve saliva samples in a way that maintains the stability of biomarkers for accurate analysis.

Tissue Collection Kits: These kits are used for collecting tissue samples, including biopsies, for histopathological analysis and research. They often include tools for sample extraction, preservation solutions, and containers for safe transport.

Other Kits: This category includes various specialized collection kits, such as those for collecting stool samples, semen samples, and environmental samples for research purposes.

By Application:

Clinical Diagnostics: In clinical diagnostics, biological sample collection kits are used for routine tests, diagnostic procedures, and disease monitoring. The demand for these kits is driven by the increasing prevalence of chronic diseases and the need for accurate and timely diagnostic results.

Research and Development: In R&D, these kits play a crucial role in genetic research, drug development, and clinical trials. The growing emphasis on personalized medicine and genomics is fueling the demand for advanced sample collection solutions.

Forensic and Legal: Biological sample collection kits are used in forensic investigations for collecting and analyzing samples related to criminal cases, paternity tests, and legal disputes. The need for reliable and tamper-evident collection solutions is driving growth in this segment.

Others: This includes applications in areas such as environmental testing and veterinary diagnostics, where sample collection kits are used to analyze biological samples from various sources.

Sample pages of Report: https://www.infiniumglobalresearch.com/form/1168?name=Sample

Regional Analysis:

North America: North America, led by the United States, is the largest market for biological sample collection kits due to the presence of advanced healthcare infrastructure, strong research and development activities, and a high prevalence of chronic diseases. The region’s focus on personalized medicine and genomics is also driving market growth.

Europe: Europe is a significant market, with countries like Germany, the UK, and France leading in the adoption of biological sample collection kits. The region’s strong emphasis on healthcare innovation, research, and diagnostics contributes to its market growth.

Asia-Pacific: The Asia-Pacific region is expected to experience rapid growth, driven by increasing healthcare investments, rising awareness of early disease detection, and expanding research activities in countries like China, India, and Japan.

Latin America and Middle East & Africa: These regions are witnessing growth due to improving healthcare infrastructure, increasing research initiatives, and a growing focus on disease prevention and diagnostics.

Emerging Trends in the Biological Sample Collection Kits Market

Several trends are shaping the future of the biological sample collection kits market. The integration of advanced technologies such as smart sensors and IoT for real-time monitoring and tracking of samples is enhancing the efficiency and accuracy of sample collection and transportation. Additionally, there is a growing trend towards user-friendly and non-invasive collection methods, such as self-collection kits for home use. The development of environmentally friendly and sustainable collection solutions is also gaining traction, driven by increasing awareness of environmental impact.

Major Market Players

BD (Becton, Dickinson and Company): BD is a global leader in medical technology, offering a wide range of biological sample collection kits, including blood collection tubes, urine collection systems, and other diagnostic solutions. The company’s focus on innovation and quality has established it as a major player in the market.

Thermo Fisher Scientific Inc.: Thermo Fisher provides a comprehensive portfolio of biological sample collection kits, including solutions for blood, saliva, and tissue collection. The company’s emphasis on research and development and its broad product range contribute to its strong market presence.

GSK (GlaxoSmithKline plc): GSK offers biological sample collection kits used in clinical trials and research. The company’s expertise in pharmaceutical research and commitment to advancing diagnostic technologies drive its growth in the market.

Qiagen N.V.: Qiagen specializes in sample and assay technologies, including biological sample collection kits for various applications. The company’s focus on molecular diagnostics and genomics supports its position as a key market player.

Simport Scientific: Simport Scientific provides a range of biological sample collection and storage solutions, including blood collection tubes and specimen containers. The company’s commitment to quality and innovation enhances its market position.

Report Overview : https://www.infiniumglobalresearch.com/market-reports/global-biological-sample-collection-kits-market

[sociomi]

SLOT TIPS YOU MUST KNOW

Gambling establishments believe that customers should be able to see opening players winning because machines at the end of lines are visible to passersby.

That is of essentially less importance today with settlements by bar-coded ticket rather than by coins dropping in a plate. There are no longer the indisputable signs of victory.

The majority of straight rounds in the current club have a similar restitution rate.

Some players who have won a lot of money and think they're hot machines like to play around. Others avoid those games because they believe they are caused by the go virus.

The opposite is also true. Some players believe that cold machines are useless. Others accept they're supposed to get hot.

In most cases, machines only notice allstreaks when they have a normal restitution rate greater than countless plays.

Late recompenses offer no indication of how a machine will perform for you, and machines are never "due" to go hot or cold.

Searching for games with bonanza images on the reels or screen but just shy of a winning combination is one way to explore close to misses.

The exploration can add a little interest to choosing a game if you're in the right mood, but near misses aren't necessarily a sign of what's to come.

Near misses do not indicate future outcomes.

With opening frameworks, too. They can make the games more interesting, but they can't change your results or get you to a winning machine.

Huge betting machine producers who supply games to live club similarly scatter their games on the web. Opportunities from well-known game developers such as Blue-blood Advances, Global Game Innovation, and Logical Games can be found by searching internet games.

However, there is a different kind of game planner that first targets the online market. Creative addresses games are made for online players by companies like NetEnt, ReelPlay, and NextGen, among others. High Five Gaming is active in the web-based market and has licensed games from major opening game developers for live play.

Video openings in live club and online spaces are basically something very similar. Similar customizations include the addition of additional prospects and reel positions populated with random numbers generated by a random number generator.

It's hard to play online games with huge, extravagant displays that move. Aside from that, developers of online slots can let their imaginations run wild and create unique extra features like the secret pursuit through the Wrongdoing Zone in NetEnt's Money Noire or the space group settlements that take the place of paylines in ReelPlay's Vast Guard.

If you're on the web and a live club most cherished catches your eye, without a doubt, play it. Regardless, endeavor games from new game makers, also. You might come across a few of the best span and spice options. Check out Indoslot.

Numerous online gambling establishments reward players who sign up to play. There might be restrictions, but in some cases, you'll get a small reward even if you don't save anything, and bigger rewards if you put money aside each month.

You'll have to use the compensation to play before you can cash anything out. It wouldn't appear to be Acceptable for a betting club to just give you free money without anticipating that you should endeavor the thing. Anyway, you can use the award money to play you as of now like or to endeavor new games before you spend your own money.

[poonamcmi]

Colorectal Cancer Screening Market Primed for Growth due to Rising Disease Prevalence

The colorectal cancer screening market involves various procedures and diagnostic tests for early detection and prevention of colorectal cancer. Some common screening methods include fecal occult blood tests, flexible sigmoidoscopy, double-contrast barium enema, and colonoscopy. Colorectal cancer screening helps detect precancerous polyps or early stage cancer that can often be treated successfully. It also aids in lowering the incidence and mortality of this preventable disease.

The global colorectal cancer screening market is estimated to be valued at US$ 15.44 Bn in 2024 and is expected to exhibit a CAGR of 7.1% over the forecast period 2024 to 2031.

Key Takeaways

Key players operating in the colorectal cancer screening market are Polymedco Inc., Eiken Chemical Co. Ltd., Sysmex Corporation, Siemens Healthineers AG, Quidel Corporation, Novigenix SA, Hemosure Inc., Exact Sciences Corp., Epigenomics Inc., Olympus Corporation, Clinical Genomics Technologies Pty Ltd., Exact Sciences Corporation, Clinical Genomics, Guardant Health, Inc., Hemosure Inc., and Geneoscopy, Inc. These players are focused on launching advanced and easy-to-use screening tests to expand their presence.

The Colorectal Cancer Screening Market Size for players to leverage the growing awareness about early detection and increase screening rates in developing countries. Companies are engaging in partnerships and collaborations to penetrate developing markets and make screening accessible to a wider population.

Globally, there is an increasing focus on population-based screening programs to reduce the burden of colorectal cancer. Several regions have implemented organized screening programs through healthcare facilities. Meanwhile, growing pilot programs in Asian and Latin American countries indicate the potential for market expansion. Market Drivers

The rapid rise in colorectal cancer incidence worldwide due to lifestyle changes, obesity, and Colorectal Cancer Screening Market Size And Trends It is estimated that the number of new cases diagnosed each year will increase by 60% by 2030. Growing disease prevalence enhances the need for widespread screening practices to detect cancer at treatable stages. Additionally, increasing reimbursement for FDA-approved screening tests, favorable government initiatives, and rising awareness about early detection are supporting the adoption of screening worldwide. PEST Analysis Political: Government regulations and healthcare reforms impact the adoption of colorectal cancer screening tests. Favorable reimbursement policies can boost the market growth. Economic: Rising healthcare expenditures and growing disposable incomes encourage people to opt for preventive healthcare check-ups including colorectal cancer screening tests. Social: Increasing awareness about early detection benefits, changing lifestyles, and growing geriatric population drive the demand for colorectal cancer screening. Technological: Advancements in biopsy techniques, endoscopy devices, diagnostic platforms enable detection of colorectal cancer at an early stage. Novel non-invasive tests based on blood, stool and CSF analysis are gaining traction.

Colorectal cancer screening market in terms of value is highly concentrated in developed regions like North America and Western Europe due to established healthcare infrastructure and widespread awareness. The United States dominates the market owing to favorable reimbursement policies and regular screening recommendations.

Asia Pacific is recognized as the fastest growing regional market for colorectal cancer screening attributed to rising healthcare spending, growing number of screening programs, and increasing incidence of colorectal cancer cases especially in China, Japan and India. Improving diagnostic capabilities and economic development are expected to boost early detection in Asia Pacific over the forecast period. Get More Insights On, Colorectal Cancer Screening Market About Author: Money Singh is a seasoned content writer with over four years of experience in the market research sector. Her expertise spans various industries, including food and beverages, biotechnology, chemical and materials, defense and aerospace, consumer goods, etc. (https://www.linkedin.com/in/money-singh-590844163

[industrynewsupdates]

Blood Screening Market Analysis, Opportunities And Forecast Report 2024-2030

The global blood screening market size was valued at USD 2.76 billion in 2022 and is anticipated to grow at a compound annual growth rate (CAGR) of 11.7% from 2023 to 2030. 

Blood screening is a process in which donated blood is screened for infectious diseases such as HBV, HCV, HIV1, and HIV2. The high growth of this market is attributed to rising blood donations, an increase in the incidence of infectious diseases, and government initiatives. According to World Health Organization (WHO), 118.54 million blood donations are collected yearly. In the U.S., 6.8 million individuals donate blood annually, and 13.6 million units of red blood cells and whole blood are collected annually.

Gather more insights about the market drivers, restrains and growth of the Blood Screening Market

The market is primarily driven by the rise in the rate of disorders such as HIV, diphtheria, measles and chronic diseases such as hemophilia, cancer, and other blood-related disorders. Blood-based diagnostics are used to diagnose a wide range of diseases, including infectious diseases, cancer, and cardiovascular diseases. Serology tests detect the presence of antibodies to a specific disease-causing organism. These tests diagnose various infectious diseases, including HIV, hepatitis B, and syphilis. Molecular tests detect the presence of DNA or RNA from a specific disease-causing organism. These tests are more sensitive than serology tests and can be used to diagnose diseases at an earlier stage. Biochemical tests measure the levels of certain substances in the blood. These tests can diagnose a wide range of diseases, including diabetes, kidney disease, and liver disease.

The COVID-19 pandemic had a significant impact on the market. Although respiratory droplets are the primary means of COVID-19 virus transmission, research has shown that viral RNA may be discovered in blood samples, supporting blood screening for COVID-19 identification, hence driving the market significantly. 

Blood Screening Market Segmentation

Grand View Research has segmented the global blood screening market based on technology, product, and region:

Technology Outlook (Revenue, USD Million, 2018 - 2030)

• Nucleic Acid Amplification Test (NAT)

• ELISA

• Chemiluminescence Immunoassay (CLIA) and Enzyme Immunoassay (EIA)

• Next Generation Sequencing

• Western Blotting

Product Outlook (Revenue, USD Million, 2018 - 2030)

• Reagent

• Instrument

Regional Outlook (Revenue, USD Million, 2018 - 2030)

• North America

o U.S.

o Canada

• Europe

o UK

o Germany

o France

o Italy

o Spain

o Sweden

o Norway

o Denmark

• Asia Pacific

o Japan

o China

o India

o Australia

o Thailand

o South Korea

• Latin America

o Brazil

o Mexico

o Argentina

• Middle East and Africa

o Saudi Arabia

o South Africa

o UAE

o Kuwait

Browse through Grand View Research's Medical Devices Industry Research Reports.

• The global embolic protection devices market size was valued at USD 612.9 million in 2023 and is projected to grow at a CAGR of 8.7% from 2024 to 2030. 

• The global covered stent market size was estimated at USD 1.13 billion in 2023 and is projected to grow at a CAGR of 4.1% from 2024 to 2030. 

Key Companies & Market Share Insights

Product launches, approvals, strategic acquisitions, and innovations are just a few of the important business strategies used by market participants to maintain and grow their global reach.

For instance, in March 2023, Abbott received U.S Food and Drug Administration (FDA) clearance for a laboratory traumatic brain injury blood test, the first commercially available lab-based test for the assessment of mild traumatic brain injuries (TBIs), commonly referred to as concussions, which will be made widely available to hospitals across the U.S. This test, which is powered by Abbott’s Alinity i laboratory tool, will enable clinicians to evaluate individuals with mild traumatic brain injuries in a timely manner.

Furthermore, in May 2023, Siemens Healthcare introduced Atellica HEMA 570 and 580 next-generation hematology analyzers, which have user-friendly interfaces and can be connected to multiple analyzers to remove workflow barriers and provide high throughput time.

Key Blood Screening Companies:

• Abbott

• Danaher Corporation (Beckman Coulter)

• Becton Dickinson and Company

• Bio-Rad Laboratories, Inc.

• Hoffman-La Roche Ltd.

• Grifols, S.A.

• Ortho-Clinical Diagnostics, Inc.

• Siemens Healthcare GmbH

• Thermo Fisher Scientific, Inc.

• SOFINA s.a (Biomerieux)

Order a free sample PDF of the Blood Screening Market Intelligence Study, published by Grand View Research. 

[industryforecastnews]

Blood Cancer Diagnostics Market To Reach USD 16.04 Billion By 2030

Blood Cancer Diagnostics Market Growth & Trends

The global blood cancer diagnostics market size is expected to reach USD 16.04 billion by 2030, registering a CAGR of 6.8% from 2024 to 2030, according to a new report by Grand View Research, Inc. The market is driven by the increasing incidence of blood malignancies, such as leukemia, lymphoma, and myeloma. The market is further expected to grow significantly due to the increasing elderly population, which is more susceptible to chronic diseases, including blood cancer. In addition, technological advancements, including NGS and other molecular diagnostic techniques, are improving the accuracy & efficiency of diagnosis, which is likely to drive the market over the forecast period.

Over the past decade, significant advancements have been made in approaches to blood cancer diagnostics, all aimed at reducing the growing incidence of diseases and their mortality. While these advancements have been well-documented to increase early cancer detection, there have been considerable advancements. For instance, NGS has enabled the analysis of the entire genome of cancer cells, providing insights into genetic mutations that guide precise diagnosis and tailored treatments. In October 2022, OGT, a Sysmex group, introduced a range of new offerings to augment its expanding NGS product suite. Notably, the SureSeq Myeloid Plus panel was designed to identify genetic mutations associated with various Myeloid disorders, enhancing the company’s capabilities in this critical area of research.

Molecular imaging techniques, such as SPECT/CT, PET, and flow cytometry, utilize molecular imaging agents to detect indicative molecular markers at different disease stages, aiding detection & monitoring. Such advancements in imaging technologies offer improved accuracy and early detection capabilities, driving the market. The global players are introducing automatic imaging tests and systems to boost their market share. For instance, in May 2023, Sysmex Corporation announced the launch of the Clinical Flow Cytometry System in Japan. The system includes Flow Cytometer XF-1600, Sample Preparation System PS-10, antibody reagents, and other related products. This system enables laboratories to automate the entire process of flow cytometry testing, from sample preparation to the reporting of measurement results, contributing to higher efficiency & testing standardization.

Governments across the world have recognized the immense healthcare burden posed by rising incidences, including hematological malignancies such as leukemia & lymphoma. In response, many countries have launched comprehensive national cancer control programs that prioritize early detection and screening efforts. For instance, the American Association of Cancer Research recently launched the Beau Biden Cancer Moonshot initiative to accelerate cancer research and make preventive screening more accessible & affordable for U.S. citizens.

Some of the key players in the market are Illumina, InVivoScribe, Ipsogen (Qiagen), Asuragen(Bio-Techne), Danaher Corporation, Abbott, SkylineDx, Adaptive Technologies, Bio-Rad Laboratories and others. These players are involved in various strategic initiatives such as product launch and approval in order to cater to a global clientele. For instance, in September 2023, Adaptive Technologies launched Epic integration for clonoSEQ, a molecular diagnostic test for MRD monitoring in blood cancers. This integration allows healthcare providers to order and review clonoSEQ test results directly within Epic's EHR system, streamlining clinical decision-making and improving patient care.

Request a free sample copy or view report summary: https://www.grandviewresearch.com/industry-analysis/blood-cancer-diagnostics-market-report

Blood Cancer Diagnostics Market Report Highlights

Based on product, the assay kits and reagents accounted for the largest revenue share of the blood cancer diagnostics market in 2023. This high share is attributable to assay kits & reagents being designed to detect specific biomarkers, genetic mutations, and other indicators, enabling healthcare professionals to diagnose & treat the disease more effectively

Based on tests, blood tests segment dominated the market and accounted for the largest share in 2023. This can be attributed to increasing innovation and availability of blood test kits for blood cancer detection

Based on end use, hospitals and clinics dominated the market with the largest share of blood cancer diagnostics market in 2023. This is attributable to growing demand in forensic labs and hospital medical labs for disease diagnosis, blood cell counts, blood typing. Furthermore, Developments in hospital laboratories are crucial to address the evolving needs of patients, and more hospitals aim to provide a wide range of services in their settings

North America dominated the market due to the presence of a large number of major market players, North America has a high prevalence of chronic diseases like leukemia These diseases require regular monitoring and diagnostic testing, fueling the demand for advanced diagnostic tools and technologies

Asia Pacific is expected to witness the fastest growth over the forecast period from 2024 to 2030, due to the presence of manufacturers with innovative devices manufacturing capabilities coupled with accelerated diagnostic research capabilities

Blood Cancer Diagnostics Market Segmentation 

Grand View Research has segmented the global blood cancer diagnostics market based on product, test, end use, and region:

Blood Cancer Diagnostics Product Outlook (Revenue, USD Million, 2018 - 2030)

Instruments

Assay Kits and Reagents

Blood Cancer Diagnostics Test Outlook (Revenue, USD Million, 2018 - 2030)

Blood Tests

Imaging Tests

Biopsy

Molecular Test

Blood Cancer Diagnostics End Use Outlook (Revenue, USD Million, 2018 - 2030)

Hospitals and Clinics

Diagnostic Labs

Research Institutes

Blood Cancer Diagnostics Regional Outlook (Revenue in USD Million, 2018 - 2030)

North America

U.S.

Canada

Mexico

Europe

UK

Germany

France

Italy

Spain

Sweden

Denmark

Norway

Asia Pacific

Japan

China

India

Australia

South Korea

Thailand

Latin America

Brazil

Argentina

Middle East and Africa

Saudi Arabia

South Africa

UAE

Kuwait

List Of Key Players in The Blood Cancer Diagnostics Market

Abbott

Illumina

InVivoScribe

Ipsogen (Qiagen)

Asuragen(Bio-Techne)

Danaher Corporation

Sequenta (Adaptive biotechnologies)

SkylineDx

Bio-Rad Laboratories

Alercell

Sophia Genetics

Browse Full Report: https://www.grandviewresearch.com/industry-analysis/blood-cancer-diagnostics-market-report